Krzyzanowska et al [15] support the idea that no significant association was found between adiponectin and risk of CVD in diabetes patients and assumed that although HMW adiponectin owned anti-inflammatory and anti-atherogenic effects, these effects play a more important role in the very early phase of atherogenesis than in manifest macrovascular disease as found in high-risk patients with type 2 DM. This evidence concerns the gene ADIPOQ and diabetes mellitus.